Xenoglim MV2 Tablet ER is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, improving insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, reducing postprandial hyperglycemia. The extended-release formulation ensures a sustained therapeutic effect, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Xenoglim MV2 is indicated as an adjunct to diet and exercise for the management of type 2 diabetes when monotherapy or dual therapy has proven insufficient. It should be used with caution in patients with renal or hepatic impairment, and regular monitoring of blood glucose levels is recommended to adjust dosage appropriately. Contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to any component. This combination therapy offers a comprehensive approach to glycemic control through multiple complementary pathways.